Goulmamine v. CVS Pharmacy, Inc.

138 F. Supp. 3d 652, 2015 U.S. Dist. LEXIS 138359, 2015 WL 5920009
CourtDistrict Court, E.D. Virginia
DecidedOctober 9, 2015
DocketCivil Action No. 3:15cv370
StatusPublished
Cited by17 cases

This text of 138 F. Supp. 3d 652 (Goulmamine v. CVS Pharmacy, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Goulmamine v. CVS Pharmacy, Inc., 138 F. Supp. 3d 652, 2015 U.S. Dist. LEXIS 138359, 2015 WL 5920009 (E.D. Va. 2015).

Opinion

MEMORANDUM OPINION

ROBERT E. PAYNE, Senior District Judge.

This matter is before the Court on Defendant CVS Pharmacy, Inc.’s MOTION TO DISMISS. (Docket No. 10). For the reasons set forth below, the motion will be granted in part and denied in part.

BACKGROUND

Plaintiff Redouane Goulmamine, M.D. is a licensed medical doctor and the sole member of Plaintiff “Midlothian Rehabilitation Associates, PLLC d/b/a The Peter-burg Spine Center.” (Compl. ¶ 8, Docket No. 1). The facts are set forth as alleged in the Complaint.

Beginning in late 2014 and continuing through early 2015, pharmacy employees at several central Virginia locations of CVS Pharmacy Inc. (“CVS”) began telling Goul-[657]*657mamine’s patients that CVS would no longer fill prescriptions written by Goul-mamine. (Compl. ¶¶ 12-15, 28). Goulma-mine and The Spine Center (hereinafter “Goulmamine”) further allege that, during these nearly two-dozen conversations, CVS employees also made:

• Factual (and incorrect) statements relating to Goulmamine: that Goulma-mine was in jail (Compl. ¶ 2S(k)), that Goulmamine had overprescribed to a pregnant patient (Compl. ¶ 23(k)), that one of Goulmamine’s patients had died from an overdose of Xanax (Compl. ¶ 23(m)), and that Goulmamine or ■ someone in his office was producing fraudulent prescriptions. (Compl. ¶230), (P)).
• Factual (and incorrect) statements relating to Goulmamine’s standing in relationship to regulatory bodies: statements that the DEA, FBI, or the Board of Medicine was investigating Goulmamine or had revoked his license. (Compl. ¶ 23(c), (g)-(i), (k), (Z),(q)). '
• Potentially misleading statements of fact: per Goulmamine’s allegations, CVS employees made several statements that “he is being investigated” or “audited,” or that he was “undér review.” (Compl. ¶ 23(e), (n), (o), (q)). These statements leave the identity of the investigator ambiguous, but in context, it is reasonable that a patiént might believe the investigator to be a regulatory or oversight body, rather • than CVS.
• Statements of opinion regarding Goul-mamine’s prescription practices: “he is filling too many prescriptions” (Compl. ¶ 23(h)) and “he writes too much pain pills and it’s against the law.” (Compl. ¶ 23(j)).
• Statements of opinion regarding Goul-mamine or Goulmamine’s relationship with his patients: “he is bad news,” (Compl. ¶ 23(c), (d)), variations on “you should find another doctor” or “your doctor won’t be in business much longer,” (Compl. ¶ 23(f), (q), (r)), and “he may lose his license.” (Compl. ¶ 23(h), (q)).
• Factual (and truthful) statements about the relationship between Goul-mamine and CVS: variations on “CVS will not fill Dr. Goulmamine’s prescriptions.” (Compl. ¶ 23(a)-(g), (i)-(s)). The Complaint also alleges that an employee stated that CVS “had problems with [Goulmamine].” (Compl. ¶230’)). ■
• Statements about third parties: criti- - eisms of patients, such as “you shouldn’t be- taking these pain pills,” “you are probably a drug addict,” and “you are just a drug addict.” (Compl. ¶ 23(b), (i), (s)).

Goulmamine states that he is, and was during the relevant time frame, in good standing with all regulatory and oversight bodies, that he has never been investigated by such bodies', and that he has never had a patient die as a- result of his prescriptions. (Compl. ¶¶ 25-26). Goulmamine states that, “[a]s a result of CVS’s campaign of defamation, Dr. Goulmamine and The Spine Center have been substantially harmed. Dr. Goulmamine is losing patients almost daily and he is also losing referrals.” (Compl. ¶ 27):

In March 2015, CVS sent Goulmamine a letter stating that it would no longer fill his prescriptions. (Compl. ¶¶ 18-21). Goulmamine alleges that

CVS told Dr. Goulmamine words to the effect that (i) he “wrote too many pain pill” prescriptions; (ii) some of his patients were “red flags”—a euphemism for drug addicts—because they were “self pay”; and (iii) because it [CVS] [658]*658takes to heart drug abuse and diversion,” it. will no longer fill his prescriptions.

(Compl. ¶ 19). Goulmamine claims that he was “so offended at the letter that he ripped it up and threw it away.” (Compl. ¶ 21). CVS attached an exhibit which CVS alleges is the March 2015 letter at Exhibit 1. (Def.’s Br., Ex. 1, Docket No. 11).

Goulmamine’s Complaint presents three claims for relief: defamation (Count I); insulting words (Count II); and tortious interference with contract/business expectancy (Count III).

DISCUSSION

CVS argues that Goulmamine has failed to state a set of facts' entitling him to relief in any of his claims.. CVS is correct, as to Counts II and III, and incorrect as to Count I.

A. Legal Standard for a Motion to Dismiss

.A motion to dismiss under Fed.R.Civ.P. 12(b)(6) challenges the- legal sufficiency of a complaint. Jordan v. Alternative Resources Corp., 458 F.3d 332, 338 (4th Cir. 2006). Federal Rule of Civil Procedure 8(a)(2) “requires only a short and plain statement of the claim showing that .the pleader is entitled- to relief, in order to give the defendant fair notice of what the ... claim is and the grounds upon which it rests.” McCleary-Evans v. Maryland Dep’t of Transp., State Highway Admin., 780 F.3d 582, 585 (4th Cir.2015) (citing Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)).

When deciding a motion to dismiss, a court “draw[s] all reasonable inferences in favor of the plaintiff.” Nemet Chevrolet, Ltd. v. Consumeraffairs.com, Inc., 591 F.3d 250, 253 (4th Cir.2009). However, while the court must “will accept the pleader’s description of what happened” and “any conclusions that can be reasonably drawn therefrom,” the court “need not accept conclusory allegations encompassing the legal effects of the pleaded facts,” Charles A. Wright & Arthur R. Miller, Federal Practice and Procedure § 1357 (3d ed.1998); Chamblee v. Old Dominion Sec. Co., L.L.C., No. 3:13CV820, 2014 WL 1415095, *4 (E.D.Va.2014). Nor is. the court required to accept as true a legal conclusion unsupported by factual allegations. Ashcroft v. Iqbal, 556 U.S. 662, 678-79, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009). “Twombly and Iqbal also made clear that the analytical approach for evaluating Rule 12(b)(6) motions to dismiss requires courts to reject conclusory allegations that amount' to mere formulaic recitation , of the elements of a claim .and to conduct a context-specific analysis to determine whether the well-pleaded factual allegations plausibly suggest an entitlement to relief.” Wright & Miller, supra; Chamblee, supra. In sum, a 12(b)(6) motion should be granted if, “after accepting all well-pleaded allegations ...

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cox v. Red Hat, Inc.
E.D. Virginia, 2024
Grover Gaming, Inc. v. Rice
W.D. Virginia, 2023
Teka v. Jack
W.D. Virginia, 2022
Doe v. Shenandoah University
W.D. Virginia, 2022
Svetlana Lokhova v. Stefan Halper
995 F.3d 134 (Fourth Circuit, 2021)
Reasor v. Walmart, Inc.
W.D. Kentucky, 2019
Steele v. Goodman
382 F. Supp. 3d 403 (E.D. Virginia, 2019)
Edwards v. Schwartz
378 F. Supp. 3d 468 (W.D. Virginia, 2019)
Northstar Aviation, LLC v. Alberto
332 F. Supp. 3d 1007 (E.D. Virginia, 2018)
Davis v. Wal-Mart Stores East, L.P.
177 F. Supp. 3d 943 (E.D. Virginia, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
138 F. Supp. 3d 652, 2015 U.S. Dist. LEXIS 138359, 2015 WL 5920009, Counsel Stack Legal Research, https://law.counselstack.com/opinion/goulmamine-v-cvs-pharmacy-inc-vaed-2015.